OA11674A
(en)
*
|
1998-11-10 |
2005-01-12 |
Janssen Pharmaceutica Nv |
HIV Replication inhibiting pyrimidines.
|
GB9914258D0
(en)
*
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
EA005423B1
(ru)
*
|
1999-09-24 |
2005-02-24 |
Янссен Фармацевтика Н.В. |
Противовирусные композиции
|
DE19945982A1
(de)
|
1999-09-24 |
2001-03-29 |
Knoll Ag |
Geschwindigkeitsbestimmte Partikel
|
ES2306671T3
(es)
|
1999-10-07 |
2008-11-16 |
Amgen Inc. |
Inhibidores de triazina quinasa.
|
CN1429222A
(zh)
|
2000-02-17 |
2003-07-09 |
安姆根有限公司 |
激酶抑制剂
|
AU782948B2
(en)
|
2000-05-08 |
2005-09-15 |
Janssen Pharmaceutica N.V. |
Prodrugs of HIV replication inhibiting pyrimidines
|
EP1282606B1
(fr)
|
2000-05-08 |
2015-04-22 |
Janssen Pharmaceutica NV |
Inhibiteurs de la replication du vih
|
EP1337931A4
(fr)
*
|
2000-11-01 |
2005-05-11 |
Snapnames Com Inc |
Systeme et procede d'acquisition et de gestion de noms de domaine
|
US6958211B2
(en)
|
2001-08-08 |
2005-10-25 |
Tibotech Bvba |
Methods of assessing HIV integrase inhibitor therapy
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
JO3429B1
(ar)
*
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
مشتقات برميدينات مثبطة فيروس الايدز
|
US8101629B2
(en)
|
2001-08-13 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
PT1438053E
(pt)
|
2001-10-17 |
2008-09-25 |
Boehringer Ingelheim Int |
Derivados de pirimidina, medicamento contendo estes compostos, sua utilização e processo para a sua preparação
|
WO2003032994A2
(fr)
|
2001-10-17 |
2003-04-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament
|
EA007578B1
(ru)
|
2001-11-01 |
2006-12-29 |
Янссен Фармацевтика Н.В. |
Производные амидов в качестве ингибиторов гликогенсинтаза-киназы 3-бета
|
CA2463822A1
(fr)
|
2001-11-01 |
2003-05-08 |
Janssen Pharmaceutica N.V. |
Heteroaryl amines utiles comme inhibiteurs de glycogene synthase kinase 3beta (inhibiteurs de gsk3)
|
SE0104140D0
(sv)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
TWI329105B
(en)
*
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
DK1485354T3
(da)
|
2002-03-13 |
2008-09-01 |
Janssen Pharmaceutica Nv |
Sulfonylamino-derivater som nye inhibitorer af histandeacetylase
|
AU2003212335B8
(en)
|
2002-03-13 |
2009-04-23 |
Janssen Pharmaceutica N.V. |
Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
EP1504047B1
(fr)
*
|
2002-05-03 |
2007-12-12 |
Janssen Pharmaceutica N.V. |
Microemulsions polymeres
|
AR039540A1
(es)
*
|
2002-05-13 |
2005-02-23 |
Tibotec Pharm Ltd |
Compuestos microbicidas con contenido de pirimidina o triazina
|
AR040456A1
(es)
|
2002-06-27 |
2005-04-06 |
Bristol Myers Squibb Co |
Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
|
MXPA05001096A
(es)
|
2002-07-29 |
2005-11-23 |
Rigel Pharmaceuticals Inc |
Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
|
KR101086678B1
(ko)
*
|
2002-08-09 |
2011-11-25 |
얀센 파마슈티카 엔.브이. |
4-[[4-[[4-(2-시아노에테닐)-2,6-디메틸페닐]아미노]-2-피리미디닐]아미노]벤조니트릴의 제조방법
|
EP2422773A3
(fr)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Séquestration de sous-unité et compositions et procédés associés
|
MXPA05005547A
(es)
*
|
2002-11-28 |
2005-07-26 |
Schering Ag |
Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
|
KR20110010824A
(ko)
|
2003-01-14 |
2011-02-07 |
아레나 파마슈티칼스, 인크. |
대사 조절제로서의 1,2,3-삼치환된 아릴 및 헤테로아릴 유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된 장애의 예방 및 치료
|
AU2004213173B2
(en)
*
|
2003-02-07 |
2010-07-29 |
Janssen Pharmaceutica N.V. |
HIV inhibiting 1,2,4-triazines
|
ES2598404T3
(es)
|
2003-02-07 |
2017-01-27 |
Janssen Pharmaceutica Nv |
Derivados de pirimidina para la prevención de infección por el VIH
|
ES2325440T3
(es)
|
2003-02-20 |
2009-09-04 |
Smithkline Beecham Corporation |
Compuestos de pirimidina.
|
CL2004000303A1
(es)
|
2003-02-20 |
2005-04-08 |
Tibotec Pharm Ltd |
Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
|
ES2667668T3
(es)
*
|
2003-07-17 |
2018-05-14 |
Janssen Sciences Ireland Uc |
Procedimiento para preparar partículas que contienen un antiviral
|
KR20120062863A
(ko)
|
2003-07-30 |
2012-06-14 |
리겔 파마슈티칼스, 인크. |
자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물
|
ATE500254T1
(de)
*
|
2003-09-25 |
2011-03-15 |
Janssen Pharmaceutica Nv |
Die replikation von hiv hemmende purinderivate
|
CA2557790A1
(fr)
|
2004-03-02 |
2005-09-15 |
Virco Bvba |
Estimations de releves cliniques
|
EP1598343A1
(fr)
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
Dérivés de 2-arylaminopyrimidines comme des inhibiteurs de PLK
|
WO2006010750A1
(fr)
|
2004-07-28 |
2006-02-02 |
Janssen Pharmaceutica N.V. |
Derives d'indolyl alkyl amine substitues utilises en tant que nouveaux inhibiteurs d'histone deacetylase
|
US7923554B2
(en)
|
2004-08-10 |
2011-04-12 |
Janssen Pharmaceutica N.V. |
HIV inhibiting 1,2,4-triazin-6-one derivatives
|
KR20070057798A
(ko)
|
2004-09-30 |
2007-06-07 |
티보텍 파마슈티칼즈 리미티드 |
Hiv를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
|
WO2006035069A1
(fr)
*
|
2004-09-30 |
2006-04-06 |
Tibotec Pharmaceuticals Ltd. |
Pyrimidines 5-substituees inhibitrices de hiv
|
AU2005288864B2
(en)
|
2004-09-30 |
2012-08-23 |
Janssen Sciences Ireland Uc |
HIV inhibiting 5-heterocyclyl pyrimidines
|
MX2007005159A
(es)
|
2004-10-29 |
2007-06-26 |
Tibotec Pharm Ltd |
Derivados de pirimidina biciclicos inhibidores del vih.
|
JP2008519073A
(ja)
*
|
2004-11-08 |
2008-06-05 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
チプラナビル及びエトラビリンの同時投与によるhiv感染症の治療法
|
CA2584295C
(fr)
|
2004-11-24 |
2014-08-26 |
Rigel Pharmaceuticals, Inc. |
Composes de spiro-2, 4-pyrimidinediamine et leurs utilisations
|
EP2161275A1
(fr)
|
2005-01-19 |
2010-03-10 |
Rigel Pharmaceuticals, Inc. |
Promédicaments de composés de 2,4-pyrimidinédiamine et leurs utilisations
|
WO2006079656A1
(fr)
*
|
2005-01-27 |
2006-08-03 |
Tibotec Pharmaceuticals Ltd. |
Derives 2-( 4-cyanophenylamino) de la pyrimidine, inhibiteurs du vih
|
ES2308731T3
(es)
|
2005-02-16 |
2008-12-01 |
Astrazeneca Ab |
Compuestos quimicos.
|
MX2007010051A
(es)
*
|
2005-02-18 |
2007-09-21 |
Tibotec Pharm Ltd |
Derivados de oxido de 2-(4-cianofenilamino)pirimidina que inhiben el virus de inmunodeficiencia humana.
|
ES2347815T3
(es)
*
|
2005-03-04 |
2010-11-04 |
Tibotec Pharmaceuticals |
2-(4-cianofenil)-6-hidroxilaminopirimidinas inhibidoras de hiv.
|
US20080287437A1
(en)
|
2005-05-16 |
2008-11-20 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
|
AU2006251163C1
(en)
*
|
2005-05-26 |
2012-07-12 |
Janssen Sciences Ireland Uc |
Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino benzonitrile
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2006133426A2
(fr)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions et procedes d'inhibition de la voie jak
|
EP1945208A4
(fr)
*
|
2005-10-06 |
2011-08-03 |
Univ Massachusetts |
Composition et synthese de nouveaux reactifs pour inhiber la replication du vih
|
PT1945631E
(pt)
|
2005-10-28 |
2012-10-15 |
Astrazeneca Ab |
Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
|
SI1981874T1
(sl)
|
2006-01-19 |
2009-10-31 |
Janssen Pharmaceutica Nv |
Aminofenilni derivati kot novi inhibitorji histon deacetilaze
|
JP5137849B2
(ja)
|
2006-01-19 |
2013-02-06 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
|
AU2007206942B2
(en)
|
2006-01-19 |
2012-08-23 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
US8962643B2
(en)
|
2006-02-24 |
2015-02-24 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
ES2465666T3
(es)
|
2006-03-30 |
2014-06-06 |
Janssen R&D Ireland |
Pirimidinas 5-amido-sustituidas inhibidoras del HIV
|
WO2007113256A1
(fr)
|
2006-03-30 |
2007-10-11 |
Tibotec Pharmaceuticals Ltd. |
Pyrimidines substituées 5-(hydroxyméthylène et aminométhylène) inhibant le vih
|
PE20120006A1
(es)
|
2006-05-15 |
2012-02-02 |
Boehringer Ingelheim Int |
Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
|
MX2008015686A
(es)
|
2006-06-06 |
2009-01-12 |
Tibotec Pharm Ltd |
Procedimiento para preparar formulaciones secadas por aspersion de etravirina.
|
KR20140079441A
(ko)
|
2006-06-19 |
2014-06-26 |
알파마 파머슈티컬스 엘엘씨 |
약제학적 조성물
|
EP2073797A2
(fr)
*
|
2006-10-11 |
2009-07-01 |
Alpharma, Inc. |
Compositions pharmaceutiques
|
US20100041687A1
(en)
|
2006-12-06 |
2010-02-18 |
Thone Daniel Joseph Christiaan |
Hydrobromide salt of an anti-hiv compound
|
EP2114902B1
(fr)
|
2006-12-29 |
2014-09-17 |
Janssen R&D Ireland |
Pymiridines substituées en 5,6, inhibitrices du vih
|
EP2114901B1
(fr)
*
|
2006-12-29 |
2014-04-09 |
Janssen R&D Ireland |
Pyrimidines substituées en position 6 inhibant le vih
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
EP2212298B1
(fr)
|
2007-10-18 |
2013-03-27 |
Concert Pharmaceuticals Inc. |
Étravirine deutérée
|
CA2709905A1
(fr)
*
|
2007-12-17 |
2009-06-25 |
Alfred Liang |
Composition d'oxycodone a l'epreuve d'un usage abusif
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
HUE035029T2
(en)
|
2008-05-21 |
2018-03-28 |
Ariad Pharma Inc |
Kinase inhibitor phosphorus derivatives
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
EP3549934A1
(fr)
|
2008-06-27 |
2019-10-09 |
Celgene CAR LLC |
Composés hétéro-aryles et leurs utilisations
|
UY32158A
(es)
*
|
2008-10-03 |
2010-04-30 |
Astrazeneca Ab |
Derivados heterociclicos y metodos de uso de los mismos
|
US20110071158A1
(en)
*
|
2009-03-18 |
2011-03-24 |
Boehringer Ingelheim International Gmbh |
New compounds
|
CA2757228C
(fr)
|
2009-03-30 |
2018-01-02 |
Tibotec Pharmaceuticals |
Co-cristal d'etravirine et de nicotinamide
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Egfr 억제제 및 질환 치료방법
|
WO2010131118A2
(fr)
*
|
2009-05-12 |
2010-11-18 |
Pliva Hrvatska D.O.O. |
Formes polymorphes d'étravirine et leurs procédés de préparation
|
UA106972C2
(uk)
|
2009-06-22 |
2014-11-10 |
Емк'Юр Фармас'Ютікалз Лімітед |
Спосіб синтезу діарилпіримідинового ненуклеозидного інгібітора зворотної транскриптази
|
US8153790B2
(en)
|
2009-07-27 |
2012-04-10 |
Krizmanic Irena |
Process for the preparation and purification of etravirine and intermediates thereof
|
GR1007010B
(el)
|
2009-10-08 |
2010-10-07 |
Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), |
Ινσουλινοειδη πεπτιδια
|
MA34299B1
(fr)
|
2010-06-04 |
2013-06-01 |
Hoffmann La Roche |
Dérivés d'aminopyrimidine au titre de modulateurs de lrrk2
|
CA2803848A1
(fr)
|
2010-06-28 |
2012-01-05 |
Hetero Research Foundation |
Procede de preparation d'intermediaire de l'etravirine et de polymorphes de l'etravirine
|
BR112013003388A2
(pt)
|
2010-08-10 |
2016-07-12 |
Celgene Avilomics Res Inc |
sal de besilato de um inibidor de btk
|
US10894787B2
(en)
|
2010-09-22 |
2021-01-19 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
JP5957460B2
(ja)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
複素環式化合物またはその使用
|
WO2012061303A1
(fr)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Composés hétéroaryle et leurs utilisations
|
AU2011328139A1
(en)
|
2010-11-10 |
2013-04-04 |
F. Hoffmann-La Roche Ag |
Pyrazole aminopyrimidine derivatives as LRRK2 modulators
|
US8796255B2
(en)
|
2010-11-10 |
2014-08-05 |
Celgene Avilomics Research, Inc |
Mutant-selective EGFR inhibitors and uses thereof
|
WO2012147104A1
(fr)
|
2011-04-26 |
2012-11-01 |
Mylan Laboratories Ltd |
Nouveau procédé de préparation d'étravirine
|
EA201391626A1
(ru)
|
2011-05-04 |
2014-03-31 |
Ариад Фармасьютикалз, Инк. |
Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
|
WO2012170647A1
(fr)
*
|
2011-06-09 |
2012-12-13 |
Assia Chemical Industriew Ltd. |
Procédé pour la préparation d'étravirine et intermédiaires dans la synthèse de celle-ci
|
CN108707151B
(zh)
|
2011-08-23 |
2022-06-03 |
阿萨纳生物科技有限责任公司 |
嘧啶并-哒嗪酮化合物及其用途
|
WO2013059572A1
(fr)
|
2011-10-19 |
2013-04-25 |
Assia Chemical Industries Ltd. |
Procédé de préparation d'etravarine et produits intermédiaires utiles dans la synthèse de ce composé
|
AR088570A1
(es)
|
2011-10-28 |
2014-06-18 |
Celgene Avilomics Res Inc |
Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
|
US8703786B2
(en)
*
|
2011-12-07 |
2014-04-22 |
Texas Southern University |
Etravirine formulations and uses thereof
|
WO2013138495A1
(fr)
|
2012-03-15 |
2013-09-19 |
Celgene Avilomics Research, Inc. |
Formes solides d'un inhibiteur de kinases du récepteur du facteur de croissance épidermique
|
CN104284584B
(zh)
|
2012-03-15 |
2019-06-04 |
西建卡尔有限责任公司 |
表皮生长因子受体激酶抑制剂的盐
|
US20150166591A1
(en)
|
2012-05-05 |
2015-06-18 |
Ariad Pharmaceuticals, Inc. |
Methods and compositions for raf kinase mediated diseases
|
WO2014068588A2
(fr)
*
|
2012-10-29 |
2014-05-08 |
Biophore India Pharmaceuticals Pvt. Ltd. |
Procédé de synthèse d'étravirine et ses intermédiaires
|
WO2014072419A1
(fr)
|
2012-11-08 |
2014-05-15 |
Universiteit Antwerpen |
Nouveaux composés anti-vih
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
KR20150126595A
(ko)
|
2012-12-21 |
2015-11-12 |
벌릭스 파마 인코포레이티드 |
간 질환 또는 증상의 치료를 위한 용도 및 방법
|
US9145387B2
(en)
|
2013-02-08 |
2015-09-29 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
EP3179858B1
(fr)
|
2014-08-13 |
2019-05-15 |
Celgene Car Llc |
Formes et compositions d'un inhibiteur d'erk
|
MX2021011472A
(es)
|
2015-01-06 |
2022-08-17 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
CN104926829A
(zh)
*
|
2015-06-08 |
2015-09-23 |
山东大学 |
一种噻吩并嘧啶类衍生物及其制备方法和应用
|
KR102603199B1
(ko)
|
2015-06-22 |
2023-11-16 |
아레나 파마슈티칼스, 인크. |
S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염
|
CN110066273A
(zh)
*
|
2019-06-05 |
2019-07-30 |
山东大学 |
一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
|
KR20220028075A
(ko)
|
2019-07-03 |
2022-03-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
|
CN111217833B
(zh)
*
|
2020-02-21 |
2021-03-16 |
山东大学 |
噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
|
CN111875548A
(zh)
*
|
2020-07-16 |
2020-11-03 |
山东大学 |
一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
|